GeneDx Holdings Investors May Seek Recovery in Securities Class Action

GeneDx Holdings Corp. (NASDAQ: WGS) is subject to a securities class action lawsuit representing investors who purchased or acquired its stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx provided misleading information concerning the expected benefits and financial impact of its acquisition of Fabric Genomics, an AI-driven genomic interpretation company.

According to the complaint, GeneDx acquired Fabric Genomics in April 2025 for up to $51 million. The company stated that the acquisition would expand its addressable market and create scalable, recurring revenue streams. These statements led investors to believe the deal would improve GeneDx's financial performance.

The situation changed in May 2026 when GeneDx released its first-quarter 2026 financial results, disclosing several negative developments. The company significantly lowered its full-year 2026 revenue guidance from $540 million-$550 million to $475 million-$490 million. Additionally, GeneDx reported a $31.2 million impairment loss attributed to Fabric Genomics.

Following these disclosures, GeneDx's stock price declined approximately 49.2%. The lawsuit claims that the company failed to adequately disclose material information regarding Fabric Genomics' viability and GeneDx's ability to achieve the anticipated benefits of the acquisition. Investors who incurred losses during the specified period must seek appointment as lead plaintiff by August 3, 2026.